3MDDS Presents New DPI Data at RDD
3M Drug Delivery Systems Presents New Dry Powder Inhaler Data at RDD
ST. PAUL, MN – April 19, 2011 – 3M Drug Delivery Systems is highlighting new data on its dry powder inhaler (DPI) technologies at the Respiratory Drug Delivery (RDD) Europe conference, May 3-6 in Berlin, Germany. The company will discuss the latest research on its DPI devices in three poster presentations, and will also present a workshop on Design for Manufacturability and Scale-Up (DFMSU) for DPI products.
The Scientific Poster Session will run Wednesday, May 4 and Thursday, May 5. 3M will present on the following topics:
• “Comparative Pulmonary Function & Pharmacokinetics of Fluticasone Propionate and Salmeterol Xinafoate in Asthmatics Using 3M Conix™ and Advair Diskus®.” This session will demonstrate the capability of the 3M Conix™ Dry Powder Inhaler to effectively and safely deliver a combination therapy to asthmatic patients in a clinical environment.• “Comparative Performance of the 3M™ Taper Dry Powder Inhaler Device,” comparing the in-vitro performance and effect of inhalation profiles for the Taper DPI relative to other DPI devices. • “Performance of a Fluticasone Propionate/Salmeterol Xinafoate Taper DPI,” characterizing the uniformity of neat fluticasone propionate (FP)/salmeterol xinafoate (SX) blends, the retention of blend uniformity through the coating process, and the performance of an FP/SX Taper DPI.
The workshop will be led by Rich Sitz, Dry Powder Inhaler Technology Platform Leader, and Steve Stein, Inhalation Development Senior Specialist, both from 3M Drug Delivery Systems. Sitz and Stein will discuss the various considerations for the early phases of development of a DPI to insure a robust and cost-effective commercial product. The session will cover topics including device design and development, process design and development, and unit cost estimating and the critical role it plays in DFMSU. The workshop will be held on Wednesday, May 4, and will be presented four times between 2:00 and 6:00 p.m. at the InterContinental Hotel.
3M’s 50-year history in inhalation continues to contribute to innovative new technologies, including the Taper and Conix DPIs. As the new data shows, these DPIs are highly efficient and patient-friendly, adding to 3M’s established portfolio of inhalation systems and components.
About 3M Drug Delivery Systems
3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop pharmaceuticals using 3M’s inhalation or transdermal drug delivery technology. 3M offers a full range of feasibility, development and manufacturing capabilities combined with regulatory guidance to help bring products to market. In-house resources, including toxicology, regulatory expertise, quality assurance, operations, and marketed product support, are available for each step of the development and commercialization process. This depth of resources is one reason why more than 50 percent of all metered-dose inhalers worldwide and 80 percent of all transdermal systems in the United States utilize 3M drug delivery technology. For more information, please visit www.3M.com/dds or call 1-800-643-8086.
3M captures the spark of new ideas and transforms them into thousands of ingenious products. Our culture of creative collaboration inspires a never-ending stream of powerful technologies that make life better. 3M is the innovation company that never stops inventing. With $27 billion in sales, 3M employs about 80,000 people worldwide and has operations in more than 65 countries. For more information, visit www.3M.com or follow @3MNews on Twitter.
3M is a trademark of 3M Company
Advair Diskus® is a regsitered trademark of GlaxoSmithKline.
Karwoski & Courage
3M Public Relations and Corporate Communications
3M Drug Delivery Systems
3M Center, Bldg. 275-3E-10
St. Paul, MN 55144